지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 242 - 248 (7page)
이용수
초록· 키워드
오류제보하기
Background/Aims: We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy.
Methods: We reviewed 63 CHB patients with genotypic resistance to LAM who showed a suboptimal response to LAM and ADV combination therapy. Among these patients, 30 were treated with ETV + ADV and 33 were treated with ETV + TDF for 12 months.
Results: The only baseline characteristic that differed significantly between the two groups was the ETV resistance profile. The rate of a virologic response [serum hepatitis B virus (HBV) DNA level of <20 IU/mL] was significant higher for ETV+TDF than for ETV+ADV over 12 months (57.6% vs. 23.3%, P=0.006, at 6 months; 84.8% vs. 26.7%, P<0.001, at 12 months). The probability of a virologic response was significantly increased in ETV+TDF (P<0.001, OR=54.78, 95% CI=7.15–419.54) and decreased in patients with higher baseline viral loads (P=0.001, OR=0.18, 95% CI=0.07–0.50) in multivariate analysis. No serious adverse event occurred during the study period.
Conclusions: In patients with CHB who showed a suboptimal response to LAM and ADV combination therapy, ETV+TDF was superior to ETV+ADV in achieving a virologic response regardless of the HBV resistance profile. Further large-scale and long-term follow-up prospective studies are needed to explain these results. (Clin Mol Hepatol 2015;21:242-248)
목차
등록된 정보가 없습니다.
참고문헌 (25)
참고문헌 신청
European Association For The Study Of The Liver / 2009 / EASL Clinical Practice Guidelines : management of chronic hepatitis B / J Hepatol 50:227~242
Keeffe EB / 2008 / A treatment algorithm for the management of chronic hepatitis B virus infection in the United States : 2008 update / Clin Gastroenterol Hepatol 6:1315~1341
Lok AS / 2009 / Chronic hepatitis B : update 2009 / Hepatology 50:661~662
Chen CJ / 2006 / Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level / JAMA 295:65~73
Iloeje UH / 2006 / Predicting cirrhosis risk based on the level of circulating hepatitis B viral load / Gastroenterology 130:678~686
Keeffe EB / 2008 / A treatment algorithm for the management of chronic hepatitis B virus infection in the United States : 2008 update / Clin Gastroenterol Hepatol 6:1315~1341
Lok AS / 2009 / Chronic hepatitis B : update 2009 / Hepatology 50:661~662
Chen CJ / 2006 / Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level / JAMA 295:65~73
Iloeje UH / 2006 / Predicting cirrhosis risk based on the level of circulating hepatitis B viral load / Gastroenterology 130:678~686
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
Clinical and Molecular Hepatology
2020 .01
-
The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy
Clinical and Molecular Hepatology
2016 .01
-
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
Clinical and Molecular Hepatology
2017 .01
-
Impact of Lamivudine Experience on the Antiviral Efficacy and Resistance Development of Entecavir in Chronic Hepatitis B Patients
Clinical and Molecular Hepatology
2015 .01
-
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
Clinical and Molecular Hepatology
2016 .01
-
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B
Gut and Liver
2020 .01
-
Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
Clinical and Molecular Hepatology
2017 .01
-
Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
Clinical and Molecular Hepatology
2017 .01
-
Efficacy of prolonged entecavir monotherapy for partial virologic response to entecavir in treatment-naïve chronic hepatitis B patients
Clinical and Molecular Hepatology
2015 .01
-
Gene expression patterns of Etv5 and Etv6 in molar tooth germs at the cap stage
대한구강해부학회지
2017 .12
-
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver
2017 .01
-
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
Clinical and Molecular Hepatology
2016 .01
-
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
Journal of Korean Medical Science
2021 .01
-
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
Gut and Liver
2020 .01
-
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
Clinical and Molecular Hepatology
2016 .01
-
Management of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver
2017 .01
-
Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study
Gut and Liver
2017 .01
-
The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
Journal of Liver Cancer
2021 .09
-
Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine- Resistant Chronic Hepatitis B
Gut and Liver
2015 .01
-
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
Journal of Liver Cancer
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0